Discovery and preclinical evaluation of anti-miR-17 oligonucleotide RGLS4326 for the treatment of polycystic kidney disease.

Nat Commun · 2019 · PMC6742637 · PMID 31515477

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

Comparative differential expression analysis showed a clear trend in global transcriptomic profiles where the expressions of dysregulated genes in the Pkd2 -KO and Pcy /CD1 cystic kidneys were improved after RGLS4326 treatment (rho = −0.559 and −0.812, respectively) (Fig. 7d, e ; y -axis).

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.